The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 935-942

  Liu, Yong Ping ^a   Ling, Yang ^a   Qi, Qiu Feng ^a   Zhang, Ya Ping ^a   Zhang, Chang Song ^a   Zhu, Chang Tai ^a   Wang, Mei Hua ^a   Pan, Yao Dong ^a  

^a China   (China)

Author keywords

Adjuvant chemotherapy; Chemosensitivity; Excision repair cross complementing gene 1; Gastric cancer; Platinum; Prognostic factor

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; OXALIPLATIN; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL VIABILITY; CHEMOSENSITIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

EID: 84872737647     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1096     Document Type: Article

References (42)

1. Leung WK, Wu MS, Kakugawa Y, et al: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9: 279-287, 2008.
2. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
3. Macdonald JS: Treatment of localized gastric cancer. Semin Oncol 31: 566-573, 2004.
4. Carrato A, Gallego-Plazas J and Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol 32: S105-S108, 2005.
5. Chipponi J, Huguier M, Pezet D, et al: Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 187: 440-445, 2004.
6. Topuz E, Basaran M, Saip P, et al: Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. Am J Clin Oncol 25: 619-624, 2002.
7. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, GradyHL and Chaney SG: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54: 3500-3505, 1994.
8. Extra JM, Espie M, Calvo F, Ferme C, Mignot L and Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303, 1990.
9. Louvet C, André T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002.
10. De Vita F, Orditura M, Matano E, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92: 1644-1649, 2005.
11. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22: 658-663, 2004.
12. Lordick F, Lorenzen S, Stollfuss J, et al: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93: 190-194, 2005.
13. Cavanna L, Artioli F, Codignola C, et al: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 29: 371-375, 2006.
14. Wei Q, Frazier ML and Levin B: DNA repair: a double-edged sword. J Natl Cancer Inst 92: 440-441, 2000.
15. Woynarowski JM, Faivre S, Herzig MC, et al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58: 920-927, 2000.
16. Reed E: ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11: 6100-6102, 2005.
17. Nuñez F, Chipchase MD, Clarke AR and Melton DW: Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21. FASEB J 14: 1073-1082, 2000.
18. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25: 2747-2754, 2007.
19. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
20. Weberpals J, Garbuio K, O'Brien A, et al: The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815, 2009.
21. Denlinger CS and Cohen SJ: Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol 8: 339-351, 2007.
22. Iqbal S, Stoehlmacher J and Lenz HJ: Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 22: 762-773, 2004.
23. Höfler H, Langer R, Ott K and Keller G: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Adv Exp Med Biol 587: 115-120, 2006.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 25: 402-408, 2001.
25. Boku N: Perspectives for personalization in chemotherapy of advanced gastric cancer. Discov Med 9: 84-89, 2010.
26. Mauer AM, Kraut EH, Krauss SA, et al: Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16: 1320-1325, 2005.
27. Suo Z, Lippard SJ and Johnson KA: Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry 38: 715-726, 1999.
28. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and HamiltonTC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003.
29. Sun JM, Ahn MJ, Park MJ, et al: Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 80: 655-660, 2011.
30. Hwang IG, Ahn MJ, Park BB, et al: ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113: 1379-1386, 2008.
31. Jun HJ, Ahn MJ, Kim HS, et al: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167-172, 2008.
32. Kwon HC, Roh MS, Oh SY, et al: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18: 504-509, 2007.
33. Kim MK, Cho KJ, Kwon GY, et al: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 44: 54-60, 2008.
34. Chang IY, Kim MH, Kim HB, et al: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327: 225-233, 2005.
35. Song L, Ritchie AM, McNeil EM, Li W and Melton DW: Identification of DNA repair gene Ercc1 as a novel target in melanoma. Pigment Cell Melanoma Res 24: 966-971, 2011.
36. Sancar A: Excision repair in mammalian cells. J Biol Chem 270: 15915-15918, 1995.
37. Darcy KM, Tian C and Reed E: A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67: 4474-4481, 2007.
38. Kudo K, Gavin E, Das S, Amable L, Shevde LA and Reed E: Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 31: 4718-4724, 2012.
39. Wei J, Zou Z, Qian X, et al: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98: 1398-1402, 2008.
40. Matsubara J, Nishina T, Yamada Y, et al: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98: 832-839, 2008.
41. Kim JS, Kim MA, Kim TM, et al: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 100: 732-738, 2009.
42. Napieralski R, Ott K, Kremer M, et al: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11: 3025-3031, 2005.